Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
02/2007
02/20/2007US7179807 5-substituted-2-arylpyrazines
02/20/2007US7179805 Microbiocides; bactericides
02/20/2007US7179804 Tachykinin receptor antagonists
02/20/2007US7179803 Method of modulating ion channel functional activity
02/20/2007US7179802 reducing the risk of developing a condition selected from the group consisting of hypercholesterolemia, atherosclerosis, low HDL levels, high LDL levels, hyperlipidemia, hypertriglyceridemia and dyslipidemia
02/20/2007US7179801 Cephem compounds
02/20/2007US7179800 Cannabinoids
02/20/2007US7179799 (3) and (6) substituted estrogenic compounds
02/20/2007US7179798 Comprises progesterone dilutions; for bone and/or joint pain
02/20/2007US7179795 Nucleic acids encoding chimeric proteins comprising BMP-2 and a proteinase inhibitor
02/20/2007US7179794 Antibiotics; bactericides
02/20/2007US7179792 Combination product of a 1,4-benzothiepine 1,1-dioxide compound with at least one other active ingredient and the use of the product
02/20/2007US7179791 Inhibiting GS-FDH to modulate NO bioactivity
02/20/2007US7179771 Composition
02/20/2007US7179647 For introducing DNA into organisms which produce large amounts of oils and, in particular, oils with a high content of unsaturated fatty acids
02/20/2007US7179646 Useful for obtaining tumour-selective gene expression in tumours having a mutated beta -catenin pathway; used to express genes encoding therapeutic proteins in colorectal cancer cells
02/20/2007US7179645 Hybrid polypeptide; induce immunology response, antiallergens; major histocompatibility complex; vaccine
02/20/2007US7179632 Process for the production of allicin
02/20/2007US7179588 Assay for the detection of paclitaxel resistant cells in human tumors
02/20/2007US7179495 Hyperforin as cytostatic agent and hyperforin ointment or cream as application form
02/20/2007US7179493 Compositions and methods for the treatment of primary and metastatic neoplastic diseases using arsenic compounds
02/20/2007US7179491 Contacting marine oil with an effective amount of a silica under a vacuum;contacting the oil with an effective amount of a bleaching clay;separating the silica from the oil; and separating the clay from the oil
02/20/2007US7179489 Mixing micronised formoterol its salt or solvate with a pre-micronised carrier/diluent at low energy, agglomerating and spheronisation or adding a coarse carrier/diluent; treating respiratory system disorders
02/20/2007US7179483 Compositions and methods for transdermal oxybutynin therapy
02/20/2007US7179482 Implant device with a retinoid for improved biocompatibility
02/20/2007US7179481 Increasing growth of epithelial cells in the female reproductive tract by administering to the vaginal cavity a retinoid or a carotenoid; treating vaginal dryness for example
02/20/2007US7179476 Medical composition for external use for dermatosis
02/20/2007US7179457 Modified to include heterologous insertion downstream of its replicase open reading frames; insertion preferably comprises one or more protein-coding regions ideal for virus-like particles packaging
02/20/2007CA2455050C Crystals including a malic acid salt of n-[2-(diethylamino) ethyl]-5-[(5-fluoro-2-oxo-3h-indole-3-ylidene) methyl]-2, 4-dimethyl-1h-pyrrole-3-carboxamide, processes for its preparation and compositions thereof
02/20/2007CA2422374C Purine derivatives
02/20/2007CA2407429C Composition for the regulation of the human immune system and the prevention and treatment of diseases thereof
02/20/2007CA2375225C Mutual salt of amlodipine and atorvastatin
02/20/2007CA2371174C Cyclo-alkyl substituted benzimidazoles and their use as parp inhibitors
02/20/2007CA2365078C Dietary compositions and methods
02/20/2007CA2344574C Thyroid receptor ligands
02/20/2007CA2335520C Adenosine derivatives
02/20/2007CA2325776C Novel analogue compounds of camptothecin, process for preparing them and pharmaceutical compositions containing them
02/20/2007CA2289979C Methods of modulating immune coagulation
02/20/2007CA2284058C Diffusional implantable delivery system
02/20/2007CA2283929C Method for treating headache pain with topical local anesthetic compositions
02/20/2007CA2270565C Progesterone for treating or reducing ischemia
02/20/2007CA2270551C Washing disinfectant for hygienic and surgical hand disinfection
02/20/2007CA2263561C Thienopyrimidines
02/20/2007CA2251086C Glycopeptide compounds
02/20/2007CA2250117C Method and composition for cleansing wounds with minimal cytotoxicity for minimal scarring
02/20/2007CA2223908C Use of squalamine for the manufacture of a medicament for inhibiting nhe
02/20/2007CA2218872C Preparation and use of sulfated oligosaccharides
02/20/2007CA2198389C Triphenylethylenes for the prevention and treatment of osteoporosis
02/20/2007CA2188567C Wet granulation formulation for bisphosphonic acids
02/20/2007CA2186784C The use of carboxylic acid derivatives as drugs
02/20/2007CA2180156C Self-assembled taxo-diperpenoid nanostructures
02/20/2007CA2151438C Thermostable trehalose-releasing enzyme, and its preparation and uses
02/20/2007CA2128044C Pharmaceutical compositions comprising a glucosidase and/or amylase inhibitor, and a lipase inhibitor
02/20/2007CA2119745C Nonpeptidyl integrin inhibitors having specificity for gpiibiiia receptor
02/19/2007CA2516745A1 Botulinum toxin in treatment of clubfoot relapse
02/15/2007WO2007019554A2 Polysaccharides for delivery of active agents
02/15/2007WO2007019550A2 Composition and method for use in cartilage affecting conditions
02/15/2007WO2007019549A2 Composition and method for use in cartilage affecting conditions
02/15/2007WO2007019540A2 Controlled release alpha-lipoic acid formulation with an inositol compound
02/15/2007WO2007019526A2 Compositions and methods for controlling glucose and lipid uptake from foods
02/15/2007WO2007019463A2 Methods of delivering therapeutics to the brain
02/15/2007WO2007019448A2 Nitric oxide enhancing angiotensin ii antagonist compounds, compositions and methods of use
02/15/2007WO2007019439A2 Block copolymer compositions and uses thereof
02/15/2007WO2007019417A1 Oxazolopyridine derivatives as sirtuin modulators
02/15/2007WO2007019416A1 Benzimidazole derivatives as sirtuin modulators
02/15/2007WO2007019378A2 Method of treating neurological disorders
02/15/2007WO2007019373A2 Novel formulations comprising fenofibrate and a statin, and related methods of treatment
02/15/2007WO2007019346A1 Benzothiazoles and thiazolopyridines as sirtuin modulators
02/15/2007WO2007019345A1 Imidazopyridine derivatives as sirtuin modulating agents
02/15/2007WO2007019344A1 Imidazo [2,1-b] thiazole derivatives as sirtuin modulating compounds
02/15/2007WO2007019308A2 Illudin analogs useful as anticancer agents
02/15/2007WO2007019255A2 Salts of vildagliptin
02/15/2007WO2007019251A2 Sphingosine kinase inhibitors and methods of their use
02/15/2007WO2007019234A2 Aminoethane sulfonamide orexin receptor antagonists
02/15/2007WO2007019224A2 Formulations and methods for enhancing the transdermal penetration of a drug
02/15/2007WO2007019221A2 Pharmaceutical compositions of silicon-containing substituted adenosine nucleoside amide analogs
02/15/2007WO2007019191A2 Thiazolopyrimidine kinase inhibitors
02/15/2007WO2007019184A2 Oral suspension of prednisolone acetate
02/15/2007WO2007019153A2 Methods for treating hypertension
02/15/2007WO2007019131A2 Use of lipid conjugates in cystic fibrosis and applications thereof
02/15/2007WO2007019130A2 Hiv integrase inhibitors
02/15/2007WO2007019116A1 Use of hdac inhibitors for the treatment of myeloma
02/15/2007WO2007019111A2 Cyclic ketal beta-secretase inhibitors for the treatment of alzheimer's disease
02/15/2007WO2007019101A2 Hiv integrase inhibitors
02/15/2007WO2007019100A2 Hiv integrase inhibitors
02/15/2007WO2007019098A2 Hiv integrase inhibitors
02/15/2007WO2007019083A1 Pyrimidine compounds as serotonin receptor modulators
02/15/2007WO2007019080A2 Tricyclic beta-secretase inhibitors for the treatment of alzheimer's disease
02/15/2007WO2007019078A2 Tricyclic beta-secretase inhibitors for the treatment of alzheimer's disease
02/15/2007WO2007019065A2 Adjuvant chemotherapy for anaplastic gliomas
02/15/2007WO2007019058A1 Tocopheryl polyethylene glycol succinate powder and process for preparing same
02/15/2007WO2007018818A1 A pyridin quinolin substituted pyrrolo [1,2-b] pyrazole monohydrate as tgf-beta inhibitor
02/15/2007WO2007018738A2 Fused bicycloheterocycle substituted quinuclidine derivatives
02/15/2007WO2007018687A1 Compositions and methods for treatment and prevention of hyperuricemia related health consequences
02/15/2007WO2007018660A2 Gabaergic imidazobenzodiazepine derivatives to treat memory deficits
02/15/2007WO2007018640A1 New capped pyrazinoylguanidine sodium channel blockers
02/15/2007WO2007018622A2 Vaginal treatment composition
02/15/2007WO2007018588A1 Stable pharmaceutical composition comprising linezolid form iv
02/15/2007WO2007018546A1 Modulation of cell fates and activities by phthalazinediones
02/15/2007WO2007018514A1 Novel m3 muscarinic acetylcholine receptor antagonists